Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

Lovshin, 2009, Incretin-based therapies for type 2 diabetes mellitus, Nat Rev, 5, 262

Parker, 2010, Molecular mechanisms underlying nutrient-stimulated incretin secretion, Exp Rev Mol Med, 12, e1, 10.1017/S146239940900132X

Mentlein, 1993, Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum, Eur J Biochem, 214, 829, 10.1111/j.1432-1033.1993.tb17986.x

Chia, 2008, Incretin-based therapies in type 2 diabetes mellitus, J Clin Endocrinol Metab, 93, 3703, 10.1210/jc.2007-2109

Deacon, 2007, Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, Diabetes Obes Metab, 9, 23, 10.1111/j.1463-1326.2007.00765.x

Nauck, 2009, Unraveling the science of incretin biology, Am J Med, 122, S3, 10.1016/j.amjmed.2009.03.012

Drucker, 2010, Incretin-based therapies for the treatment of type 2 diabetes; evaluation of the risks and benefits, Diabetes Care, 33, 428, 10.2337/dc09-1499

Butler, 2010, Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?, Diabetologia, 53, 1, 10.1007/s00125-009-1591-5

Denker, 2006, Exenatide (exendin-4)-induced pancreatitis: a case report, Diabetes Care, 29, 471, 10.2337/diacare.29.02.06.dc05-2043

Tripathy, 2008, Exenatide and acute pancreatitis, J Assoc Physicians India, 56, 987

Cure, 2008, Exenatide and rare adverse events, N Engl J Med, 358, 1969, 10.1056/NEJMc0707137

2009

Monami, 2008, Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials, Diabetes Care, 31, 1455, 10.2337/dc07-2308

Matveyenko, 2009, Beneficial endocrine but adverse exocrine effects of sitagliptin in the HIP rat model of type 2 diabetes, interactions with metformin, Diabetes, 58, 1604, 10.2337/db09-0058

Nachnani, 2009, Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas, Diabetologia, 58, 1604

Jura, 2005, Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between, Cell Res, 15, 72, 10.1038/sj.cr.7290269

Rebours, 2009, The natural history of hereditary pancreatitis: a national series, Gut, 58, 97, 10.1136/gut.2008.149179

Havre, 2008, The role of CD26/dipeptidyl peptidase IV in cancer, Front Biosci, 13, 1634, 10.2741/2787

Matteucci, 2009, Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme, Curr Med Chem, 16, 2943, 10.2174/092986709788803114

2009

Dore, 2009, Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide, Curr Med Res Opin, 25, 1019, 10.1185/03007990902820519

Williams-Herman, 2008, Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis, BMC Endocr Disord, 8, 14, 10.1186/1472-6823-8-14

Celinski, 2009, Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma)-specific agonist, as a modulator in experimental acute pancreatitis, Med Sci Monit, 15, BR21

Fernandes-Santos, 2009, Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet, Pancreas, 38, e80, 10.1097/MPA.0b013e3181987d9d

Blomgren, 2002, Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis, Diabetes Care, 25, 298, 10.2337/diacare.25.2.298

Currie, 2009, The influence of glucose-lowering therapies on cancer risk in type 2 diabetes, Diabetologia, 52, 1766, 10.1007/s00125-009-1440-6

Shetty, 2005, Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes, J Manag Care Pharm, 11, 559

Coughlin, 2004, Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults, Am J Epidemiol, 159, 1160, 10.1093/aje/kwh161

Gale, 2009, Collateral damage: the conundrum of drug safety, Diabetologia, 52, 1975, 10.1007/s00125-009-1491-8

Poluzzi, 2010, Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System, Drug Saf, 33, 303, 10.2165/11531850-000000000-00000

Chen, 2008, Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms, Ann Pharmacother, 42, 1791, 10.1345/aph.1L315

Hauben, 2004, Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms, Eur J Clin Pharmacol, 60, 747, 10.1007/s00228-004-0834-0

White, 2009, Efficacy and safety of incretin based therapies: clinical trial data, J Am Pharm Assoc (2003), 49, S30, 10.1331/JAPhA.2009.09079

Montanya, 2009, A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus, Clin Ther, 31, 2472, 10.1016/j.clinthera.2009.11.034

Garg, 2010, Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis, Diabetes Care, 33, 2349, 10.2337/dc10-0482

Bhanot, 2009, Mechanisms of parenchymal injury and signaling pathways in ectatic ducts of chronic pancreatitis: implications for pancreatic carcinogenesis, Lab Invest, 89, 489, 10.1038/labinvest.2009.19

Tatarkiewicz, 2010, Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents, Am J Physiol Endocrinol Metab, 299, E1076, 10.1152/ajpendo.00479.2010

Stulc, 2010, Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?, Diabetes Res Clin Pract, 88, 125, 10.1016/j.diabres.2010.02.017

Li, 2009, Antidiabetic therapies affect risk of pancreatic cancer, Gastroenterology, 137, 482, 10.1053/j.gastro.2009.04.013

Strobel, 2010, Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia, Gastroenterology, 138, 1166, 10.1053/j.gastro.2009.12.005

Li, 2011, Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies, Cancer Causes Control, 22, 189, 10.1007/s10552-010-9686-3